SOMAÍ Pharmaceuticals is expanding its reach to Ireland, partnering with Georgelle Pharmaceutical Ltd. to bring a comprehensive range of cannabis-based medicines to Irish patients. This marks SOMAÍ’s fifth international expansion this year, following its successful ventures in the UK, Australia, Germany, and Poland.
Under a three-year agreement, SOMAÍ will supply Irish cannabis-prescribing clinics with a diverse selection of cannabinoid-containing products, including THC, CBD, and balanced oral solutions. The product line will further expand to include terpene-infused oral solutions and inhalation extracts, designed to address specific patient needs.
Michael Sassano, founder and interim CEO of SOMAÍ, emphasizes the significance of this partnership, stating, “Bringing Irish patients a full range of products and choices will further increase the range of demographics that need medicinal cannabis and have suffered with few options to treat themselves.” This partnership aims to improve accessibility to cannabis-based medicines in Ireland, where patients have previously faced limited treatment options.
Daniel O’Brien, CSO of Georgelle, expresses enthusiasm about the collaboration, stating, “We admire [SOMAÍ’s] commitment to innovation and making a positive impact… to significantly improve the portfolio of available medicines for Irish patients.” This move positions SOMAÍ as a leader in the Irish medical cannabis market, continuing its mission to offer patients enhanced treatment options tailored to their individual needs.
This strategic partnership signifies a significant step forward for the Irish healthcare system, providing patients with greater access to alternative treatments and improving their overall well-being.
